TP 9201

a platelet integrin alphaIIbbeta3 (GPIIb/IIIa) antagonist; a synthetic RGD-containing cyclic peptide; may be effective in prevention of re-thrombosis after thromolytic therapy without adversely affecting hemostasis

Also Known As:

TP-9201; TP9201; acetyl-L-cysteinyl-L-asparaginyl-L-propyl-L-arginyl-glycyl-L-alpha-aspartyl-o-methyl-L-tyrosyl-L-arginyl-L-cysteine amide, cyclic 1-9 sulfide; L-Cysteinamide, N-acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginylglycyl-L-alpha-aspartyl-O-methyl-L-tyrosyl-L-arginyl-, cyclic (1-9)-disulfide

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

Thrombosis (Thrombus)

09/01/1997 - "Infusion of high-dose TP-9201 was associated with a significant reduction in the thrombus mass as compared with the control vessels. "
01/07/1994 - "One of these analogues, TP9201, has been shown to inhibit platelet-mediated thrombus formation without associated prolongation of template bleeding time. "
01/01/1994 - "Administration of TP9201 in hamsters inhibited in vivo thrombus formation with ID50 of 30 micrograms/kg, ex vivo platelet aggregation with an ID50 of 50 micrograms/kg and bolus injection of 1 mg/kg did not prolong the template bleeding time. "
09/01/1993 - "TP9201 may be an effective therapy for the prevention of re-thrombosis after thrombolytic therapy without adversely affecting hemostasis."
09/01/1993 - "A synthetic RGD-containing cyclic peptide, TP9201, specific for the platelet alpha IIb beta 3 receptor complex, was tested for its ability to accelerate thrombolysis and prevent reocclusion in experimentally induced coronary artery thrombosis. "

Related Drugs and Biologics

1.	Cyclic Peptides

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Therapeutics